Union Therapeutics said that a Phase 1 SAD/MAD trial of UNI911 dry powder niclosamide in 44 healthy volunteers was completed successfully, confirming the safety of the inhaled formulation. The company recently acquired an option for rights to the dry powder formulation from TFF Pharmaceuticals and intends to develop it as a DPI for the treatment of COVID-19.
Union CEO and co-founder Rasmus Toft-Kehler commented, “Confirming the safety of UNI911 in healthy volunteers is a major milestone achieved in record speed, which has only been possible due to the extraordinary support and dedication of all involved parties. It provides further evidence that UNI911 is a uniquely differentiated candidate for prophylaxis and treatment of COVID-19. The team is now entirely dedicated to moving UNI911 into COVID-19 patients as rapidly as possible.”
Read the Union Therapeutics press release.
